However, a significant proportion of EGFR-positive tumors display inherent or acquired resistance to the treatment attributed to mutations in the components of the EGFR-dependent pathway (e.g., EGFR, K-/N-ras) or activation of alternative cancer-related pathways (8). Here, EGFR is linked to cancer.